BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zegers CM, van Elmpt W, Hoebers FJ, Troost EG, Öllers MC, Mottaghy FM, Lambin P. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. Acta Oncol 2015;54:1378-84. [PMID: 26213313 DOI: 10.3109/0284186X.2015.1062913] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Kirsch CFE. Squamous Cell Cancer: Mucosal, Nodal and Extranodal Disease. Hybrid PET/MR Neuroimaging 2022. [DOI: 10.1007/978-3-030-82367-2_56] [Reference Citation Analysis]
2 Yuan H, Palmer GM, Dewhirst MW. Imaging Hypoxia. Molecular Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00074-0] [Reference Citation Analysis]
3 Busk M, Horsman MR, Overgaard J, Jakobsen S. Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes. Acta Oncol 2019;58:1476-82. [PMID: 31432722 DOI: 10.1080/0284186X.2019.1648864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Betts HM, O'Connor RA, Christian JA, Vinayakamoorthy V, Foweraker K, Pascoe AC, Perkins AC. Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancers: a pilot study for integration into treatment planning. Nucl Med Commun 2019;40:73-8. [PMID: 30371605 DOI: 10.1097/MNM.0000000000000933] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Grau C, Høyer M, Poulsen PR, Muren LP, Korreman SS, Tanderup K, Lindegaard JC, Alsner J, Overgaard J. Rethink radiotherapy - BIGART 2017. Acta Oncol 2017;56:1341-52. [PMID: 29148908 DOI: 10.1080/0284186X.2017.1371326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Even AJG, Reymen B, La Fontaine MD, Das M, Jochems A, Mottaghy FM, Belderbos JSA, De Ruysscher D, Lambin P, van Elmpt W. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. Acta Oncol 2017;56:1591-6. [PMID: 28840770 DOI: 10.1080/0284186X.2017.1349332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
7 Mottaghy FM. Non-invasive molecular imaging and theranostic probes. Methods 2017;130:1-3. [PMID: 28987915 DOI: 10.1016/j.ymeth.2017.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Lindblom E, Dasu A, Uhrdin J, Even A, van Elmpt W, Lambin P, Wersäll P, Toma-Dasu I. Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function. Acta Oncol 2017;56:819-25. [PMID: 28464740 DOI: 10.1080/0284186X.2017.1293289] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
9 Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer 2016;16:644. [PMID: 27535748 DOI: 10.1186/s12885-016-2709-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
10 Grau C, Overgaard J, Høyer M, Tanderup K, Lindegaard JC, Muren LP. Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. Acta Oncol 2015;54:1245-50. [PMID: 26390238 DOI: 10.3109/0284186X.2015.1076992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]